Aduro BioTech Secures $19,250,000 Series B Funding Round

  • Feed Type
  • Date
    4/20/2011
  • Company Name
    Aduro BioTech
  • Mailing Address
    626 Bancroft Way Berkeley, CA 94710
  • Company Description
    Aduro BioTech is a clinical-stage immunotherapy company with a platform technology for therapeutic and prophylactic vaccines for cancer and infectious diseases. The platform of attenuated and targeted vaccines based on Listeria monocytogenes has been in development for nine years.
  • Website
    http://www.adurobiotech.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $19,250,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    This new round of funding enables us to advance our lead cancer vaccine, CRS-207, into a Phase 2 clinical trial in pancreatic cancer. In addition, these funds will support initial clinical development of CRS-207 for other indications and preclinical development of therapeutic vaccines for prostate cancer and melanoma as well as prophylactic vaccines for malaria and tularemia.
  • M&A Terms
  • Venture Investor
    Morningside Group
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.